ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
0.00
0.00
(0.00%)
Closed April 28 4:00PM
0.00
0.00
(0.00%)

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

BAY News

Official News Only

BAY Discussion

View Posts
Pastortec Pastortec 1 week ago
BAYER i recommend buy VOIS. The company that sell the stocks sell with them all its patents and one of them can influence with certain on your future sales.
πŸ‘οΈ0
mm41 mm41 2 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 2 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 2 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 2 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 2 months ago
The cheapest blue-chip stock . buy for a good long term
πŸ‘οΈ0
debunker1 debunker1 6 years ago
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
πŸ‘οΈ0
trendmkr trendmkr 8 years ago
A Look at the Science Behind Bayer’s Latest Buy

http://marketexclusive.com/a-look-at-the-science-behind-bayers-latest-buy/1194/
πŸ‘οΈ0
MasterofCoin15 MasterofCoin15 9 years ago
this stock don't play... up 50% since last year..
πŸ‘οΈ0
dragonball dragonball 15 years ago
how come this board is dead?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
Yes, hope so eom
πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
well it must be good if it made it to phase 3
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
maybe its a cancer drug? dont know oncological maybe. ?
πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
very true. I will be picking up 100 shares and just letting it ride you think it might dip a bit?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
no,if Management has time to talk to me, they are not busy enough. I will let them be the PPS is good imo

πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
what exactly does nexevar do?
πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
seriously though this looks like a pretty good company have you spoken to management?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
then you are about to move on up, to the east side to a deluxe apartment in the sky when you take this new brand of bayer pill lol
πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
yes i do

πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
Knowing your alias you take the dollar store brand lol

j/k
πŸ‘οΈ0
JT_Marlin JT_Marlin 18 years ago
Is this bayer like the one in my medicine cabinet
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 18 years ago
Bayer And Onyx Say 39% Progress On Phase III Nexavar Trial In Patients With Advanced Kidney Cancer - Quick Facts [BAY]

11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.

Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.

The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.

http://realtimetraders.com/sp/breakingnews.asp?vid=9625264



πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock